<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordsOutput xmlns:ns2="local"><serviceExecutionTime>326</serviceExecutionTime><Drug id="54058"><DrugName>zolmitriptan (iontophoretic patch, migraine), Vyteris</DrugName><DrugNamesKey><Name id="42757002">zolmitriptan</Name></DrugNamesKey><DrugSynonyms><Name><Value>zolmitriptan</Value><Types><Type>USAN</Type><Type>BAN</Type><Type>INN</Type></Types></Name><Name><Value>zolmitriptan (iontophoretic patch, migraine), Vyteris</Value></Name><Name><Value>139264-17-8</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="1003916">Vyteris Inc</CompanyOriginator><CompaniesSecondary><Company id="1003916">Vyteris Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="1003916" type="Company"><TargetEntity id="4295911067" type="organizationId">Vyteris Inc</TargetEntity></SourceEntity><SourceEntity id="210" type="ciIndication"><TargetEntity id="G43" type="ICD10"></TargetEntity><TargetEntity id="10027599" type="MEDDRA"></TargetEntity><TargetEntity id="D008881" type="MeSH"></TargetEntity><TargetEntity id="-672899670" type="omicsDisease"></TargetEntity><TargetEntity id="27" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="8" type="Action"><TargetEntity id="221" type="Mechanism">5-HT1B Agonists</TargetEntity></SourceEntity><SourceEntity id="10" type="Action"><TargetEntity id="222" type="Mechanism">5-HT1D Agonists</TargetEntity></SourceEntity><SourceEntity id="PTGT-00012" type="ciTarget"><TargetEntity id="60721888233513" type="siTarget">5-hydroxytryptamine receptor 1B</TargetEntity><TargetEntity id="-1751497305" type="omicsTarget"></TargetEntity></SourceEntity><SourceEntity id="PTGT-00015" type="ciTarget"><TargetEntity id="35177128833523" type="siTarget">5-hydroxytryptamine receptor 1D</TargetEntity><TargetEntity id="-2105063808" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C1">Phase 1 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="210">Migraine</Indication></IndicationsSecondary><ActionsPrimary><Action id="10">5-HT 1d receptor agonist</Action><Action id="8">5-HT 1b receptor agonist</Action></ActionsPrimary><ActionsSecondary><Action id="2946">Analgesic</Action></ActionsSecondary><Technologies><Technology id="558">Transdermal formulation</Technology><Technology id="600">Patch formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>N2C</Code><Name>ANTI-MIGRAINE PREPARATIONS</Name></Ephmra><Ephmra><Code>N2</Code><Name>ANALGESICS</Name></Ephmra></EphmraCodes><LastModificationDate>2017-08-16T12:49:28.000Z</LastModificationDate><ChangeDateLast>2011-05-20T12:17:05.000Z</ChangeDateLast><AddedDate>2005-09-21T12:44:56.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1003916" linkType="Company"&gt;Vyteris&lt;/ulink&gt; was developing a patch formulation of &lt;ulink linkID="4736" linkType="Drug"&gt;zolmitriptan&lt;/ulink&gt;, delivered using its transdermal Actyve iontophoretic patch technology, for the potential treatment of migraine [&lt;ulink linkID="624019" linkType="Reference"&gt;624019&lt;/ulink&gt;];   [&lt;ulink linkID="1149515" linkType="Reference"&gt;1149515&lt;/ulink&gt;]. In September 2005, positive results were reported from a phase I trial [&lt;ulink linkID="624019" linkType="Reference"&gt;624019&lt;/ulink&gt;]; in November 2010, development was ongoing   [&lt;ulink linkID="1149515" linkType="Reference"&gt;1149515&lt;/ulink&gt;]. However, in May 2011, the company initiated a strategic plan to become a CRO and discontinued its drug delivery business. At that time, Vyteris planned to monetize its transdermal drug delivery assets [&lt;ulink linkID="1193054" linkType="Reference"&gt;1193054&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In September  2005, Vyteris reported phase I trial data of the formulation. Transdermal delivery using two electrical current profiles was compared to oral administration of zolmitriptan in 14 healthy volunteers. The first profile rapidly delivered the drug, followed by a lower sustained release. The second profile provided a bolus-like input 3 h after commencing iontophoretic administration. Blood plasma zolmitriptan concentrations followed the applied current profile, and any instances of skin irritation were mild and resolved quickly [&lt;ulink linkID="624019" linkType="Reference"&gt;624019&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1003916">Vyteris Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="210">Migraine</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2011-05-19T00:00:00.000Z</StatusDate><Source id="1193054" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1003916">Vyteris Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="210">Migraine</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2005-09-20T00:00:00.000Z</StatusDate><Source id="624019" type="PR"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00012"><Name>5-HT 1b receptor</Name><SwissprotNumbers><Swissprot>O08892</Swissprot><Swissprot>P28222</Swissprot><Swissprot>P28334</Swissprot><Swissprot>P28564</Swissprot><Swissprot>P35404</Swissprot><Swissprot>P46636</Swissprot><Swissprot>P49144</Swissprot><Swissprot>P56496</Swissprot><Swissprot>P60020</Swissprot><Swissprot>P79250</Swissprot><Swissprot>P79399</Swissprot><Swissprot>Q6XXX8</Swissprot><Swissprot>Q9N2B7</Swissprot></SwissprotNumbers></Target><Target id="PTGT-00015"><Name>5-HT 1d receptor</Name><SwissprotNumbers><Swissprot>P11614</Swissprot><Swissprot>P28221</Swissprot><Swissprot>P28565</Swissprot><Swissprot>P49145</Swissprot><Swissprot>P79400</Swissprot><Swissprot>P79748</Swissprot><Swissprot>Q60484</Swissprot><Swissprot>Q61224</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><StructureSmiles><Smiles>CN(C)CCc1c[nH]c2c1cc(cc2)C[C@H]3COC(=O)N3</Smiles></StructureSmiles><hasSWOTs>N</hasSWOTs></Drug></ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordsOutput>